Analysts See $-0.30 EPS for Coupa Software (COUP); Carnegie Capital Asset Management Has Decreased Abbvie (ABBV) Holding

February 22, 2018 - By David Stenberg

Carnegie Capital Asset Management Llc decreased Abbvie Inc (ABBV) stake by 3.85% reported in 2017Q3 SEC filing. Carnegie Capital Asset Management Llc sold 5,700 shares as Abbvie Inc (ABBV)’s stock rose 6.17%. The Carnegie Capital Asset Management Llc holds 142,453 shares with $13.48 million value, down from 148,153 last quarter. Abbvie Inc now has $187.24B valuation. The stock decreased 0.06% or $0.07 during the last trading session, reaching $117.91. About 5.12 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since February 22, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Analysts expect Coupa Software Incorporated (NASDAQ:COUP) to report $-0.30 EPS on March, 12 after the close.They anticipate $0.18 EPS change or 150.00% from last quarter’s $-0.12 EPS. After having $-0.19 EPS previously, Coupa Software Incorporated’s analysts see 57.89% EPS growth. The stock increased 1.84% or $0.77 during the last trading session, reaching $42.62. About 1.31M shares traded or 108.55% up from the average. Coupa Software Incorporated (NASDAQ:COUP) has 0.00% since February 22, 2017 and is . It has underperformed by 16.70% the S&P500.

Coupa Software Incorporated provides cloud spend management platform. The company has market cap of $2.35 billion. The company's platform connects organization with suppliers globally; and provides visibility into and control over how companies spend money, as well as enables businesses to achieve savings that drive profitability. It currently has negative earnings. The Company’s platform consists of procurement, invoicing, and expense management modules that form its transactional engine and capture a company's spend under management; and offers supporting modules, including sourcing, analytics, contract management, supplier management, inventory management, and storefront that help companies further manage their spend.

Carnegie Capital Asset Management Llc increased Las Vegas Sands Corp (NYSE:LVS) stake by 10,644 shares to 19,597 valued at $1.24M in 2017Q3. It also upped Select Sector Spdr Tr (XLF) stake by 12,992 shares and now owns 143,167 shares. Ishares Tr (IBMH) was raised too.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 9 Hold. Therefore 48% are positive. Abbvie Inc had 78 analyst reports since July 21, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $9400 target in Friday, July 14 report. The stock has “Buy” rating by Jefferies on Thursday, January 4. The company was downgraded on Monday, October 31 by Credit Suisse. On Monday, September 25 the stock rating was downgraded by UBS to “Neutral”. The firm has “Equal-Weight” rating by Barclays Capital given on Friday, October 13. The rating was downgraded by Morgan Stanley on Wednesday, June 8 to “Equal-Weight”. The stock of AbbVie Inc. (NYSE:ABBV) earned “Market Perform” rating by Cowen & Co on Monday, June 6. Raymond James initiated AbbVie Inc. (NYSE:ABBV) on Friday, September 2 with “Outperform” rating. Deutsche Bank upgraded AbbVie Inc. (NYSE:ABBV) rating on Thursday, September 28. Deutsche Bank has “Hold” rating and $88.0 target. Jefferies maintained AbbVie Inc. (NYSE:ABBV) on Monday, July 17 with “Buy” rating.

Since September 11, 2017, it had 0 buys, and 6 selling transactions for $25.71 million activity. Gosebruch Henry O also sold $1.66M worth of AbbVie Inc. (NYSE:ABBV) shares. Schumacher Laura J sold $14.07 million worth of AbbVie Inc. (NYSE:ABBV) on Thursday, December 14. Michael Robert A. sold $119,351 worth of stock. The insider SALEKI-GERHARDT AZITA sold $705,655. RICHMOND TIMOTHY J. also sold $8.57M worth of AbbVie Inc. (NYSE:ABBV) shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 David Stenberg

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: